http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-088630-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ce92a4d2fdab0cc5440f710c3787f38 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-541 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 |
| filingDate | 2012-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f123a272ca256e14b6cdf3f0c39718c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a153a6fee75f190aa9885c831bb59bc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8549a5c327276bf5e539e2c4617e8fc9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b0b36a30774fef728d09ee81371e8d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23e42e1f88f86b8e12648b9ec0cb8aac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d23acaef21e863b44f620f1da9cf757 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce811cce08bb9469e7ced83275f908e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f91388c910ccfbcf887f67fabd673d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a39e4ec50eae51b79b6e6b2e3358219f |
| publicationDate | 2014-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-088630-A1 |
| titleOfInvention | HEPATITIS C VIRUS INHIBITORS |
| abstract | Claim 1: A compound characterized in that it is of formula (1), wherein R¹ is selected from C₁₋₆ alkyl, C₁₋₆ alkoxy, phenyl, C₃₋₆ cycloalkyl, heterocycle, and heteroaryl, wherein C₁₋₆ alkyl is optionally substituted with -ORᵃ, amino, -SRᵉ, heterocycle, or heteroaryl, C₁₋₆ alkoxy is optionally substituted with -ORᵃ, and heterocycle is optionally substituted with -ORᵃ, amino, or -C (O) O-C₁₋₆ alkyl, or with one or two C₁₋₃ or = O alkyl; R² is selected from hydrogen and C₁₋₆ alkyl; R³ is selected from hydrogen, C₁₋₆ alkyl, -C (O) O-C₁₋₆ alkyl, -C (O) NRᵐRⁿ, -C (O) C₃₋₆ cycloalkyl, and -S (O) ₁₋₃C₁₋₃ alkyl ; or R² and R³ together with the nitrogen atom to which they are attached form a heterocycle; R⁴ is selected from C₁₋₆ alkyl, -NRᵇRᶜ, -ORᵈ, -SRᵉ, -S (O) C₁₋₃ alkyl, -S (O) ₁₋₃C₁₋₃ alkyl, -CN, C (O) NRᵃRᵇ, heterocycle, heteroaryl , and halo, where C₁₋₆ alkyl is optionally substituted with -ORᵃ; and R⁵ and R⁶ are hydrogen; or R⁴ and R⁵ are independently C alquilo alkyl or halo and R⁶ is hydrogen; or R⁴ and R⁵ taken together form - (CH₂) ₙ-, where n is 2, 3, 4, or 5; and R⁶ is hydrogen; or R⁴ and R⁵ taken together form -O- (CH₂) ₂-O- and R⁶ is hydrogen; or R⁴ is hydrogen and R⁵ and R⁶ taken together form - (CH₂) ₘ-, where m is 1, 2, 3, or 4; or R⁴ and R⁵ are each hydrogen and R⁶ is C₁₋₆ alkyl; R⁷ is selected from halo, C₁₋₃ alkyl, and C₁₋₃ alkoxy where C₁₋₃ alkyl and C₁₋₃ alkoxy are optionally substituted with one, two, three, four, or five halo; R⁸ is C₁₋₃ alkyl, optionally substituted with -ORʰ; R⁹ is selected from C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, -NRᶠRᵍ, heteroaryl, heterocycle, and -CH₂-heteroaryl; where: C₁₋₆ alkyl is optionally substituted with one or two substituents independently selected from -ORʰ, -NRʲRᵏ, -NHC (O) C₁₋₃ alkyl, -NHC (O) O-C₁₋₃ alkyl, -NHC ( O) C₃₋₆ cycloalkyl, C₃₋₆ cycloalkyl, halo, -NHC (O) C₁₋₃ (O) alkyl ORʰ, -NHC (O) C₁₋₃Rʰ alkyl, -NHC (O) NH-C₁₋₃ alkyl, -NHS (O) ₁₋₃C₁₋₃ alkyl, and heterocycle; C₁₋₆ alkoxy is optionally substituted with -ORʰ; any C₃₋₆ cycloalkyl is optionally substituted with one, two or three substituents independently selected from C₁₋₃ alkyl, halo, NRᵃRᵇ, -ORʰ, and -CD₃, where any C₁₋₃ alkyl is optionally substituted with one, two or three halo; any heterocycle is optionally substituted with one, two or three substituents independently selected from C₁₋₃ alkyl, halo, -C (O) O-C₁₋₃ alkyl, -C (O) C₁₋₆ alkyl, -C (O ) C₃₋₆ cycloalkyl, -C (O) NH-C₁₋₆ alkyl, -C (O) NH-C₃₋₆ cycloalkyl, -S (O) ₁₋₆C₁₋₆ alkyl, and -C (O) NH₂; where any -C (O) C₁₋₆ alkyl is optionally substituted with -NHC (O) O-C₁₋₃ alkyl, -ORʰ, -NRʲRᵏ, or heterocycle, any -C (O) C₃₋₆ cycloalkyl is optionally substituted with one or two C₁₋₃ alkyl, and any -C (O) NH-C₁₋₆ alkyl is optionally substituted with -ORʰ or C₃₋₆ cycloalkyl; any heteroaryl is optionally substituted with one or two C₁₋₃ alkyl; Rᵃ, Rᵇ, Rᵉ, Rʰ, Rʲ, Rᵏ, Rᵐ, and Rⁿ are independently of each other hydrogen or C₁₋₃ alkyl; Rᶜ is hydrogen or C₁₋₆ alkyl, where C₁₋₆ alkyl is optionally substituted with -ORᵃ or amino; Rᵈ is hydrogen or C₁₋₆ alkyl, where C₁₋₆ alkyl is optionally substituted with -ORʰ or with heteroaryl optionally substituted with C₁₋₃ alkyl; Rᶠ is hydrogen or C₁₋₆ alkyl, where C₁₋₆ alkyl is optionally substituted with -ORʰ; Rᵍ is selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl, NRᵃRᵇ, and heterocycle, where C₁₋₆ alkyl is optionally substituted with -ORʰ and heterocycle is optionally substituted with one or two = O; R¹⁰ is selected from hydrogen, halo, and C₁₋₃ alkyl, where C₁₋₃ alkyl is optionally substituted with one, two or three halo, or with -ORʰ; Aₘ is -NHC (O) - or -C (O) NH-; a is 0, 1 or 2; and b is 0, 1 or 2; or a pharmaceutically acceptable salt or stereoisomer thereof. |
| priorityDate | 2011-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.